Manufacturer Supplying High Quality Linezolid API with CAS: 165800-03-3

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• Purity: >99%
• Appearance: White Powder
• Model NO.: Frazer-Linezolid
• Shelf Life: 2 Years
• Storage: Keep in Cool and Dry Place
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• MOQ: 1kg
• Shipping Area: Worldwide/All Countries
• CAS: 165800-03-3
• Mf: C16h20fn3o4
• MW: 337.35
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

Manufacturer Supplying High Quality Linezolid API with CAS: 165800-03-3

Specification of Analysis

Item	Test Standard		Testing Result
Appearance	Powder		Complies
Color	White fine Powder		Complies
Particle Size	100% pass 80 mesh		Complies
Oder	Characteristic		Complies
Taste	Characteristic		Complies
Loss on Drying	≤5.0%		2.20%
Residue on Ignition	≤0.1%		0.05%
Residual ac'etone	≤0.1%		Complies
Residual Ethanol	≤0.5%		Complies
Heave Mentals	≤10ppm		Complies
Na	≤0.1%		<0.1%
Pb	≤3 ppm		Complies
Total Plate	<1000CFU/g		Complies
Yeast & Mold	<100 CFU /g		Complies
E. Coli	Negative		Complies
Salmonella	Negative		Complies
Conclusion: Conform with USP Standard

Description
Linezolid is a antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be use for a variety of other infections.As a protein synthesis inhibitor, it stops the growth of bacteria by disrupting their production of proteins, that is, it is a bacteriostatic agent, not bacteriocidal. Although many antibiotics work this way, the exact mechanism of action of linezolid appears to be unique in that it blocks the initiation of protein production, and not one of the later steps. Bacterial resistance to linezolid has remained very low since it was first detected in 1999, although it may be increasing. It is a member of the oxazolidinone class of drugs.

Medical Use
The main indication of linezolid is the treatment of severe infections caused by Gram-positive bacteria that are resistant to other antibiotics; it should not be used against bacteria that are sensitive to drugs with a narrower spectrum of activity, such as penicillins and cephalosporins. In both the popular press and the scientific literature, linezolid has been called a "reserve antibiotic"-one that should be used sparingly so that it will remain effective as a drug of last resort against potentially intractable infections.
In the United States, the indications for linezolid use approved by the U.S. Food and Drug Administration (FDA) are the treatment of vancomycin-resistant Enterococcus faecium infections, with or without bacterial invasion of the bloodstream; nosocomial pneumonia (hospital-acquired) and community-acquired pneumonia caused by S. aureus or S. pneumoniae; complicated skin and skin structure infections (cSSSI) caused by susceptible bacteria, including diabetic foot infection, unless complicated by osteomyelitis (infection of the bone and bone marrow); and uncomplicated skin and soft tissue infections caused by S. pyogenes or S. aureus.The manufacturer advises against the use of linezolid for community-acquired pneumonia or uncomplicated skin and soft tissue infections caused by MRSA.In the United Kingdom, pneumonia and cSSSIs are the only indications noted in the product labeling.